Anaesthetic exemption for adjuvant muscle relaxant recognized, but relief depends on operative classification list period.

Neocuron, a pancuronium bromide-based non-depolarising muscle relaxant used as an adjuvant to anaesthesia during surgery, is treated as an anaesthetic for exemption under the cited notifications. The text also notes that final relief depends on verification of whether the approved classification list, earlier accepted without challenge, remained operative during the disputed period; that limited factual question requires fresh decision before consequential relief can follow.

---

---

Issues: (i) whether the product Neocuron, based on pancuronium bromide, qualified as an anaesthetic so as to obtain exemption under Notifications 6/94 and 114/94; (ii) whether the matter required verification of the operative period and effect of the approved classification list.

Issue (i): whether the product Neocuron, based on pancuronium bromide, qualified as an anaesthetic so as to obtain exemption under Notifications 6/94 and 114/94.

Analysis: The product was shown by the chemical examiner's report and medical material to be a non-depolarising muscle relaxant used as an adjuvant to anaesthesia during surgery. The evidence from standard medical references and doctors' certificates supported the view that, in modern anaesthetic technique, such a drug forms part of balanced anaesthesia and is used for the purpose of surgical anaesthesia. The substance was therefore treated as belonging to the class of anaesthetic products for the purpose of the exemption notifications.

Conclusion: The issue was decided in favour of the assessee, and Neocuron was held to be eligible for exemption under the notifications.

Issue (ii): whether the matter required verification of the operative period and effect of the approved classification list.

Analysis: The order recorded that the classification list had earlier been approved by denying the notification benefit, and no appeal had been filed against that approval. The record did not clearly show whether that approval remained operative during the disputed period. The factual position had to be verified before final relief could follow.

Conclusion: The issue was remitted to the Assistant Commissioner for fresh decision on the limited question of the operative period of the approved classification list.

Final Conclusion: The assessee succeeded on the substantive exemption issue, but the matter was sent back for limited factual verification before consequential relief could be granted.

Ratio Decidendi: A drug used as an adjuvant to anaesthesia in surgical anaesthesia may qualify as an anaesthetic for exemption purposes, but relief may still depend on the operative effect of an unchallenged approved classification list during the relevant period.

---